Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Prognostic Nomogram of Extranodal NK/T-cell Lymphoma: A Multi-center Retrospective Study

This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.

Study Overview

• Status: Recruiting
• Conditions: Extranodal NK/T-cell Lymphoma

Detailed Description

This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL between January 1, 2000 and August 31, 2020; (2) Patients older than 18 years. The pathology of initial diagnosis was reviewed by designated pathologists.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Hua Wang; Phone Number: +862087342462; Email: wanghua@sysucc.org.cn

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Recruiting
      • Sun Yat-Sen University Cancer Center
      • Contact: hua wang, MD.; Phone Number: 0086-02087342462; Email: wanghua@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

1. Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020;
2. Patients older than 18 years.

Description

Inclusion Criteria:

• Patients newly diagnosed with ENKTL
• Patients diagnosed between January 1, 2000 and August 31, 2020
• Patients older than 18 years

Exclusion Criteria:

• Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Training cohort; Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
Validation Cohort; Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Time between the date of diagnosis and any kinds of death	5 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival	Time between the date of diagnosis and any kinds of death or relapse/progression	5 year

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Investigators: Principal Investigator: Hua Wang, Sun Yat-sen University

Study record dates

Study Major Dates

• Study Start (Actual): August 28, 2020
• Primary Completion (Estimated): January 1, 2024
• Study Completion (Estimated): January 1, 2024

Study Registration Dates

• First Submitted: September 12, 2020
• First Submitted That Met QC Criteria: September 12, 2020
• First Posted (Actual): September 18, 2020

Study Record Updates

• Last Update Posted (Estimated): June 16, 2023
• Last Update Submitted That Met QC Criteria: June 15, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Extranodal NK-T-Cell
• Other Study ID Numbers: ENKTL-2020

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No